Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 4/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | F7 | P08709 | 1/20 | 0.64 |
| ▸ | F3 | P13726 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.57 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.57 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.57 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.57 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.57 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.57 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CCND1 | P24385 | 2/20 | 0.52 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2610117 | 0.90 | HSD17B10 (0.77) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL31025143 | 0.90 | HSD17B10 (0.77) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL27811127 | 0.87 | HSD17B10 (0.79) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL11803848 | 0.86 | LMNA (0.71) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL8109983 | 0.86 | NR4A2 (0.67) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL2659416 | 0.85 | NR4A2 (0.71) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL4240354 | 0.83 | NR4A2 (1.00) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL22864436 | 0.83 | NR4A2 (0.63) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL7287695 | 0.83 | LMNA (0.68) | NR4A2LMNARAB9AKDM4EHSD17B10 | |
| SCHEMBL27651981 | 0.83 | NR4A2 (0.63) | NR4A2LMNARAB9AKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1083059-A | The indoles that 3-piperidine methyl carboxylicesters replaces | GLAXO GROUP LTD (GB) | 1994-03-02 | — | — | CN | claimed |
| EP-4665326-A1 | A PHARMACEUTICAL COMPOSITION TARGETING MUTANT P53 AND HER2 | Dr Dozo Laboratories (IN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | BLACK DIAMOND THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| CN-119306651-A | Indole 3-amide derivative and preparation method and application thereof | 山东大学 | 2025-01-14 | — | — | CN | disclosed |
| WO-2024171213-A9 | A PHARMACEUTICAL COMPOSITION TARGETING MUTANT P53 AND HER2 | DR DOZO LABORATORIES (IN) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024171213-A1 | A PHARMACEUTICAL COMPOSITION TARGETING MUTANT P53 AND HER2 | DR DOZO LABORATORIES (IN) | 2024-08-22 | — | — | WO | disclosed |
| EP-4399210-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | Black Diamond Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118159537-A | 6-Aza-quinoline derivatives and related uses | 黑钻治疗公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117756785-A | Preparation and application of N- (pyridine-2-yl) benzo [ b ] five-membered heterocycle-3-carboxamide structure compound | 江西中医药大学 | 2024-03-26 | — | — | CN | disclosed |
| CN-117603123-A | Novel indole HDAC6 small molecule inhibitor, preparation method and application | 郑州大学 | 2024-02-27 | — | — | CN | disclosed |
| EP-2058306-A1 | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives | SCHWARZ PHARMA AG (DE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008076805-A2 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2007070818-A1 | SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070816-A2 | THIOPHENE DERIVATIVES AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007070826-A1 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-21 | — | — | WO | disclosed |
| WO-1998028292-A1 | NOVEL PIPERIDINE CONTAINING COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-02 | — | — | WO | disclosed |
| EP-0501322-B1 | 3-Piperidinylmethylcarboxylate substituted indoles | GLAXO GROUP LTD (GB) | 1996-09-04 | — | — | EP | disclosed |
| CN-1083059-A | The indoles that 3-piperidine methyl carboxylicesters replaces | GLAXO GROUP LTD (GB) | 1994-03-02 | — | — | CN | disclosed |
| WO-1992014727-A1 | 3-PIPERIDINYLMETHYLCARBOXYLATE SUBSTITUTED INDOLES | GLAXO GROUP LIMITED (GB) | 1992-09-03 | — | — | WO | disclosed |
| EP-0501322-A1 | 3-Piperidinylmethylcarboxylate substituted indoles | GLAXO GROUP LIMITED (GB) | 1992-09-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017914-A1 | 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES | TOP2A, TOP2B, UGT2B7 | NR4A2 2340/4885LMNA 2740/4885RAB9A 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.